AKT signaling secondary to up-regulation of IGF-1R has also been implicated in having an inferior outcome in ARMS patients with stage III disease, suggesting a way to risk stratify patients (Petricoin et al., 2007). This evidence concerns the gene IGF1R and alveolar rhabdomyosarcoma.